English News
China’s regulatory authority accepts Fosun Pharma clinical trial application of mRNA vaccine candidate
BNT162b2, the second vaccine candidate introduced by Fosun Pharmaceutical Industrial, is a preventive biological product intended to be used on people aged between 18 and 85 for preventing COVID-19.